SLC5A2 and chronic kidney disease: Newer GLMs, especially sodium glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP1RAs), have been increasingly prescribed to non-transplant patients with chronic kidney disease (CKD), with or without T2D [5].